Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 12/20 | 0.44 |
| ▸ | CTPS2 | Q9NRF8 | 4/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075244 | 1.00 | CTPS1 (0.44) | CTPS1CTPS2GPR27MAPK1CLK1 | |
| SCHEMBL22490837 | 0.82 | CTPS1 (0.51) | CTPS1CTPS2 | |
| SCHEMBL22490722 | 0.82 | CTPS1 (0.64) | CTPS1CTPS2 | |
| SCHEMBL22490755 | 0.82 | CTPS1 (0.64) | CTPS1CTPS2 | |
| SCHEMBL21076986 | 0.81 | CTPS1 (0.58) | CTPS1CTPS2MAPK1 | |
| SCHEMBL30420461 | 0.81 | CTPS1 (0.58) | CTPS1CTPS2MAPK1 | |
| SCHEMBL22490808 | 0.80 | CTPS1 (0.49) | CTPS1CTPS2 | |
| SCHEMBL22490781 | 0.80 | CTPS1 (0.58) | CTPS1CTPS2 | |
| SCHEMBL22490827 | 0.74 | CTPS1 (0.52) | CTPS1CTPS2 | |
| SCHEMBL24088638 | 0.73 | CTPS1 (0.44) | CTPS1CTPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885GPR27 2979/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885GPR27 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.